Participants will be assessed for study drug effects on incontinence at Baseline (prior to dosing) and at weeks 4 and 24 post dosing by cystometry. At Screening (V1) and at 2, 8 and 24 weeks post dosing participants will have a bladder scan to evaluate for residual volume.